© 2004 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2004 Oxford University Press
NEWS |
Medicare Cost Containment Strategy Targets Several Oncology Drugs
| The first 150 words of the full text of this article appear below. |
At the same time that new targeted therapies are making their debuts in cancer clinics—at a cost set by their pharmaceutical manufacturers of often thousands of dollars a dose, and tens of thousands per treatment course—the federal government announced that it plans to slash Medicare reimbursement prices for some common chemotherapy drugs by as much as 81% below current levels.
"It is at least as bad as we thought it could be," said Deborah Kamin, senior director for policy and clinical affairs at the American Society of Clinical Oncology (ASCO). "The Congressional Budget Office had anticipated [cuts in reimbursement amounts] of $300 million, but this is $500 million. These are big, big cuts."
With the sampling of proposed reimbursement amounts in hand, private
practice oncologists are now trying to "guestimate" how much they
may lose starting Jan. 1, 2005, in reimbursements on cancer drugs they give to
their Medicare patients.
Bid to Freeze Reimbursement Levels
Oncologists in Private Practice
"No Political Will"
Difficult Decisions
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. M. Shea, L. H. Curtis, B. G. Hammill, L. D. DiMartino, A. P. Abernethy, and K. A. Schulman Association Between the Medicare Modernization Act of 2003 and Patient Wait Times and Travel Distance for Chemotherapy JAMA, July 9, 2008; 300(2): 189 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gratwohl, H. Baldomero, A. Schwendener, M. Gratwohl, J. Apperley, D. Niederwieser, K. Frauendorfer, and for the Joint Accreditation Committee of the Inter Predictability of hematopoietic stem cell transplantation rates Haematologica, December 1, 2007; 92(12): 1679 - 1686. [Abstract] [Full Text] [PDF]
|
|